Status:

WITHDRAWN

Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients

Lead Sponsor:

Institute of Liver and Biliary Sciences, India

Conditions:

Chronic Hepatitis B

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Combination therapies using nucleos(t)ide analogues lead to higher viral suppression although it may not be sustained for long. Also it remains unknown if combination of more potent analogues is more ...

Eligibility Criteria

Inclusion

  • HBeAg negative at screening
  • Documented chronic Hepatitis B
  • Treatment naive
  • Compensated liver disease

Exclusion

  • Chronic Hepatitis B with Child Pugh B \& C
  • HBeAg positive
  • Decompensated liver disease

Key Trial Info

Start Date :

June 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01260610

Start Date

June 1 2011

End Date

June 1 2011

Last Update

June 16 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Institute of Liver & Biliary Sciences

New Delhi, India

Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients | DecenTrialz